ホーム › 急性骨髄性白血病 › オハイオ › Cincinnati
Cincinnati、OHにおける急性骨髄性白血病の臨床試験
Cincinnatiとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- 他3件
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
被験者募集中観察研究
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Oncology Hematology Care, Cincinnati
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
被験者募集中第1相
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
被験者募集中観察研究
- University of Cincinnati, Cincinnati
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
被験者募集中第3相
- US-Cincinnati OH-CINCY, Cincinnati
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
被験者募集中第3相
- US-Cincinnati OH-CINCY, Cincinnati
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
被験者募集中第1相
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15マイル先
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
被験者募集中第1相
- Cincinnati Children's Hospital Medical Center, Cincinnati
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
被験者募集中第3相
- University of Cincinnati Medical Center (University Hospital), Cincinnati
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Cincinnati Children's Hospital, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
被験者募集中第1相
- Cincinnati Children's Hospital, Cincinnati
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
被験者募集中第1/2相
- Cincinnati Children's Hospital Medical Center, Cincinnati
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
被験者募集中第1相
- Cincinnati Children's Hospital Medical Center, Cincinnati
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
被験者募集中第2相
- Cincinnati Children's Hospital Medical Center, Cincinnati
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
被験者募集中第1相
- Oncology Hematology Care, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
被験者募集中第1相
- University of Cincinnati, Cincinnati
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Baldwin Park, CA40件の研究
- Seattle, WA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA30件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Cincinnatiにおける他の研究
- 非小細胞肺癌35件の研究
- がん（全種類）27件の研究
- 乳がん25件の研究
- 心不全24件の研究
- 大腸癌21件の研究
- 転移性癌20件の研究
- 卵巣がん19件の研究
- 肺がん19件の研究
- 肥満症19件の研究
- 前立腺がん18件の研究
- 多発性骨髄腫17件の研究
- 悪性黒色腫17件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。